NextGen MRI System for Personalized Medicine Research
Nanalysis (with RS2D) Wins European Competitive Bid with NextGen MRI System for Personalized Medicine Research
STRASBOURG, France, Dec. 10, 2020 /CNW/ – Nanalysis Scientific Corp. (Nanalysis), (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), through its subsidiary RS2D S.A.S. (RS2D), is pleased to announce that it has won a C$1.2M non-repayable grant to further leverage its proprietary Nuclear Magnetic Resonance Imaging (MRI) technology for smart NextGen clinical MRI systems. This product, based on the Cameleon4TM Original Equipment Manufacturer (OEM) product, will advance these devices an additional step towards the personalized medicine of the future.
This project combines our Cameleon4TM technology, used in our benchtop and high-field NMR products, with our NextGen software, in partnership with leaders in personalized medicine and high sensitivity MRI technology such as Haute Ecole Specialisée de Suisse Occidental in Basel, Switzerland. MRI is a very powerful and widely used diagnostic technique, but it has a known weakness: Sensitivity. The main objective of this project is to demonstrate that tremendous sensitivity gains can be achieved using magnetic resonance to activate gamma emissions. Combined with Artificial Intelligence software techniques, this can lead to life-saving medical solutions in the near future.”
For more details, please read the article.